HAYWARD, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals (Nasdaq:ANTH) today announced that Anthera has received formal notice from The NASDAQ Stock Market LLC (“Nasdaq”) indicating that the Company has evidenced full compliance with all requirements for continued listing on The Nasdaq Capital Market, including the $35 million market value of listed securities requirement, which compliance was required by the Nasdaq Hearings Panel on or before May 14, 2018.
“We are pleased to have achieved full compliance with the Nasdaq listing requirements and to have this matter closed with Nasdaq. We continue to focus on bringing our Phase 3 RESULT study of Sollpura in patients with exocrine pancreatic insufficiency to completion and remain on track to report topline data in the coming days,” said Craig Thompson, President & CEO of Anthera Pharmaceuticals, Inc.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing products to treat serious and life-threatening diseases, including exocrine pancreatic insufficiency and B-cell associated renal diseases, including IgA nephropathy. Additional information on the Company can be found at www.anthera.com.
Safe Harbor Statement
Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including but not limited to those set forth in Anthera's public filings with the SEC, including Anthera's Annual Report on Form 10-K for the year ended December 31, 2017. Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.
Investor Relations of Anthera Pharmaceuticals, Inc.
For Media Inquiries:
Frannie Marmorstein, 305-567-0821
Source: Anthera Pharmaceuticals, Inc.